MSI-H is associated with TP53 mutations and high tumor mutation burden (TMB), which leads to tumor immunogenicity and stimulates the host anti-tumor immune response, thereby being sensitive to immune checkpoint inhibitors (ICIs). The gene discussed is TP53; the disease is neoplasm.